Receive our newsletter – data, insights and analysis delivered to you
  1. News
August 8, 2017

Rebiotix starts enrolment in Phase III trial of RBX2660 for C. diff infection

US-based clinical-stage microbiome firm Rebiotix has started patient enrolment in a Phase III clinical trial of RBX2660 to prevent recurrent Clostridium difficile (C. diff) infection.

US-based clinical-stage microbiome firm Rebiotix has started patient enrolment in a Phase III clinical trial of RBX2660 to prevent recurrent Clostridium difficile (C. diff) infection.

RBX2660 is developed using the firm’s Microbiota Restoration Therapy (MRT) platform, which is a stabilised drug technology that delivers spore and non-spore forming microbes into patient’s intestinal tract to restore healthier state of a dysbiotic gut.

The randomised, double-blind, multi-centre, placebo-controlled Phase III trial is designed to investigate the efficacy and safety of RBX2660 at clinical sites in the US and Canada.

While the trial’s primary endpoint is the proportion of subjects with treatment success after a blinded RBX2660 therapy, the treatment success will act as prevention of recurrent infection for eight weeks.

"Initiating the Phase III clinical study of RBX2660 is a significant milestone for Rebiotix and showcases the potential of our MRT platform to enable the development of microbiome-directed drug products."

Rebiotix president and CEO Lee Jones said: “We plan to continue our strong momentum generated by our Phase II results in this Phase III trial as we seek to advance RBX2660 toward registration and potential approval so patients have an option for this unmet medical need.

Content from our partners
Africa’s last mile: Building viable vaccine supply chains
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success
Patient-centric pharma logistics: How CRYOPDP delivers hope worldwide

“Initiating the Phase III clinical study of RBX2660 is a significant milestone for Rebiotix and showcases the potential of our MRT platform to enable the development of microbiome-directed drug products.”

RBX2660’s Phase II programme for the prevention of C. diff infection included three separate Phase II trials, one of which was conducted as a randomised, double-blind, placebo controlled Phase IIb study.

The RBX2660 is reported to have been evaluated in up to 300 subjects to date, with a 24-month follow-up following treatment.


Image: Clostridium difficile bacteria. Photo: courtesy of Janice Carr/CDC.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU